Products

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC23266	MUT-A	MUT-A is a novel potent, HIV-1 Integrase IN-LEDGF allosteric inhibitor, shows potent anti-HIV activity with EC50 of 32 nM and 12 nM for NL4-3 or HxB2 HIV-1 strains, respectively.
DC10915	mutant EGFR inhibitor B30 Featured	mutant EGFR inhibitor B30 is a potent, selective, next-generation EGFR mutants inhibitor with IC50 of 1.1 and 7.2 nM for EGFRL858R and EGFRL858R/T790M/C797S, respectively.
DC21924	mutant IDH1 inhibitor VVS	mutant IDH1 inhibitor VVS is a potent, selective mutant IDH1 inhibitor with nanomolar potency against both IDH1 R132H and IDH1 R132C, efficiently suppresses the cell-based production of D-2-HG in an HEK293 mutant embryonic kidney cell line..
DC7982	Mutant IDH1-IN-1 Featured	Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent).
DC20258	MW150 (MW01-18-150SRM)	MW150 (MW01-18-150SRM) is a selective, brain penetrant p38αMAPK, which is efficacious in diverse animal models of neurologic disorders.
DC11829	MW-150 Featured	MW-150 is a novel potent, selective, CNS penetrant and orally active inhibitor of p38α MAPK with Ki of 101 nM
DC11828	MW-150 hydrochloride	MW-150 is a novel potent, selective, CNS penetrant and orally active inhibitor of p38α MAPK with Ki of 101 nM
DC21355	MW181	MW181 (MW01-10-181SRM) is an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK with Ki of 184 nM, no affitnity for CK1δ.
DC21356	MW181 dihydrochloride	MW181 (MW01-10-181SRM) is an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK with Ki of 184 nM, no affitnity for CK1δ.
DC21357	MW181 hydrochloride	MW181 (MW01-10-181SRM) is an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK with Ki of 184 nM, no affitnity for CK1δ.
DC26051	MX1013 Featured	MX1013 is a dipeptide pan-caspase inhibitor that inhibits caspase-1
DC22170	MX106	MX106 is a novel potent survivin inhibitor, effectively suppresses MDA-MB-231 cells proliferation with IC50 of 2.2 uM.
DC22171	MX107	MX107 is a novel potent survivin inhibitor, effectively suppresses MDA-MB-231 cells proliferation with IC50 of 3.1 uM.
DC10074	MX69 Featured	MX69 is the MDM2/XIAP inhibitor, used for cancer treatment.
DC21925	MY10	MY10 is a small-molecule inhibitor of RPTPβ/ζ (PTPRZ1) with IC50 of 0.1 uM, significantly increases the phosphorylation of key tyrosine residues of RPTPβ/ζ substrates involved in neuronal survival and differentiation.
DC21926	MY33-3	MY33-3 is a small-molecule inhibitor of RPTPβ/ζ (PTPRZ1) with IC50 of 0.1 uM, significantly increases the phosphorylation of key tyrosine residues of RPTPβ/ζ substrates involved in neuronal survival and differentiation.
DC10952	MYCMI-6(NSC 354961) Featured	MYCMI-6 (NSC354961) is a selective, high affinity inhibitor of MYC-MAX interaction, blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with Kd of 1.6 uM in SPR assay.
DC9138	Mycophenolate Mofetil	Mycophenolate mofetil is a prodrug for mycophenolic acid, a potent inhibitor of inosine monophosphate dehydrogenase (IC50 = 11 nM). Inhibition of this enzyme blocks de novo GTP generation as well as RNA and DNA synthesis in lymphocytes. In this way, mycop
DCAPI1127	Mycophenolic (Mycophenolate)	Mycophenolic (Mycophenolate)
DC10606	Mycro-3 Featured	Mycro 3 is potent and selective for c-Myc in whole cell assays.
DC21927	Myokinasib	Myokinasib is a mixed-type, selective inhibitor of Myosin Light Chain Kinase 1 (MLCK1) with IC50 of 7.9 uM, can bind to the free enzyme and the enzyme-substrate complex.
DC20469	myomiRs-IN-1	myomiRs-IN-1 is a small-molecule probe that selectively inhibits myogenic microRNAs (myomiRs) including miR-1, miR-133a, and miR-206.
DC21360	MZ1 Featured	MZ1 is a PROTAC that tethers JQ1 to a ligand for the E3 ubiquitin ligase VHL, triggers, induces degradation of the BET bromodomain BRD4.
DC22172	MZH29	MZH29 is a novel potent, selective, orally active type II FLT3 inhibitor with IC50 of 9 nM and 7 nM against FLT3-WT and FLT3-ITD, respectively.
DC8428	Lomitapide Mesylate	N-(2,2,2-trifluorethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-9H-fluorene-9-carboxamide methanesulfonate
DC9298	thiotepa Featured	N,N’N’-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group.
DC23254	N.41	N.41 (HIV inhibitor N.41, Vif inhibitor N.41) is a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G (A3G) protein (IC50=2.2 uM).
DC8271	NSC-41589 Featured	N-[2-(methylsulfanyl) phenyl]acetamide.
DC21107	N1-hexyl-N5-benzyl-biguanide mesylate	N1-hexyl-N5-benzyl-biguanide mesylate (HBB) is a potent and specific inhibitor of CYP3A4 AA epoxygenase activity with IC50 of 9.5 uM for inhibition of CYP3A4-mediated (±)-14,15-EET synthesis.
DC10359	N2-Methylguanine	N2-Methylguanine is a modified nucleoside. N2-Methylguanine is an endogenous methylated nucleoside found in human fluids.

Products

Customized Consultation X

Your information is safe with us. * Required Fields.